In the CARE-HF trial, elevated galectin-3 levels were significantly associated with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony, highlighting its role in fibrosis and adverse remodeling [39]. The gene discussed is LGALS3; the disease is hydrops fetalis.